ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,213Medicare Part D Prescriptions Filled, Including Refills

Rank: 29 out of 546

$712K Total Retail Price of All Prescriptions

Rank: 21 out of 546

409 Patients Receiving at Least One Drug in Part D
59%Patients 65 Years and Older
83% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maine
Lower avg

Schedule Two
Controlled Substances

18% of this provider’s 409 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

20% of this provider’s 409 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 4,485 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$70 was the average price of a prescription from this provider, compared to $65 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maine
HYDROCODONE-ACETAMINOPHEN 526 185 S3 1 8
LEVOTHYROXINE SODIUM 463 154 2 3
OMEPRAZOLE 430 204 3 4
OXYCODONE HCL 281 89 S2 4 15
SIMVASTATIN 276 179 5 2
LISINOPRIL 251 167 6 1
ATENOLOL 189 146 7 12
FUROSEMIDE 170 94 8 5
CITALOPRAM HBR 164 76 9 21
ZOLPIDEM TARTRATE 160 84 10 26
METFORMIN HCL 156 110 11 10
PANTOPRAZOLE SODIUM 146 36 12 18
HYDROCHLOROTHIAZIDE 138 92 13 7
AMLODIPINE BESYLATE 131 102 14 9
RANITIDINE HCL 128 21 15 23
METOPROLOL SUCCINATE 122 78 16 17
METHADONE HCL 121 19 S2 17 61
GABAPENTIN 119 20 18 16
ATORVASTATIN CALCIUM 119 78 18 11
CYCLOBENZAPRINE HCL 116 26 R 20 34
METOPROLOL TARTRATE 115 61 21 6
PREDNISONE 114 63 22 29
TRAZODONE HCL 112 32 23 25
TRAMADOL HCL 110 57 24 19
COMBIVENT 104 32 25 71
PROAIR HFA 97 0 26 27
SERTRALINE HCL 89 27 27 14
IBUPROFEN 83 15 28 70
CARBAMAZEPINE 79 0 29 120
MIRTAZAPINE 78 32 30 51
POLYETHYLENE GLYCOL 3350 76 13 31 68
ESCITALOPRAM OXALATE 74 21 32 66
TOPIRAMATE 72 0 33 174
LAMOTRIGINE 70 18 34 125
VENLAFAXINE HCL ER 68 42 35 88
DONEPEZIL HCL 68 44 35 31
AMITRIPTYLINE HCL 68 13 R 35 48
TAMSULOSIN HCL 66 33 38 35
DIVALPROEX SODIUM 62 0 39 78
LOVASTATIN 60 38 40 22
NEXIUM 59 0 41 52
AZITHROMYCIN 58 32 42 55
FENTANYL 57 0 S2 43 50
ADVAIR DISKUS 56 23 44 20
SPIRIVA 52 31 45 28
PREMARIN 52 31 R 45 150
CYMBALTA 51 17 47 37
VERAPAMIL ER 51 12 47 110
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 22, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.